AMGN Amgen Inc.

+4.71  (+2%)
Previous Close 199.31
Open 201.83
Price To Book 11.33
Market Cap 122,351,043,312
Shares 599,701,222
Volume 3,004,345
Short Ratio
Av. Daily Volume 3,117,389

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 2H 2020.
Tezepelumab - NAVIGATOR
Approval announced May 21, 2018.
Prolia (denosumab)
Glucocorticoid-induced osteoporosis (GIOP)
sNDA approval announced June 11, 2018.
Relapsed Multiple Myeloma
sBLA approval announced June 29, 2017.
Vectibix (Panitumumab)
Wild-Type RAS Metastatic Colorectal Cancer
Approved September 14, 2017.
MVASITM (bevacizumab-awwb)
Biosimilar candidate to Avastin (bevacizumab)
Approved April 15, 2015.
Chronic Heart Failure
Approval announced May 17, 2018.
Phase 3 ongoing. Expected completion 2024.
CNP 520
Alzheimer’s Disease
Approval announced December 1, 2017.
Cardiovascular disease
sBLA approval announced January 5, 2017.
Multiple Myeloma
FDA approval announced October 1, 2018.
Multiple Myeloma
sNDA approved January 17, 2018.
Relapsed Multiple Myeloma
PDUFA date under priority review August 14, 2017. Approval announced July 11, 2017.
Phase 3 data released January 24, 2019 - primary endpoint met in rheumatoid arthritis trial. Non-Hodgkin’s lymphoma data due 3Q 2019.
ABP 798
RITUXAN biosimilar - non-Hodgkin lymphoma
FDA approval announced June 13, 2019.
ABP 980 (Kanjinti; trastuzumab-anns)
Herceptin biosimilar
BsUFA date December 14, 2019.
ABP 710
REMICADE biosimilar - rheumatoid arthritis
Approved February 7, 2017.
Secondary hyperparathyroidism (SHPT)
FDA Approval announced April 9, 2019.
EVENITY (Romosozumab)
Phase 3 interim analysis 1H 2020.
Omecamtiv mecarbil GALACTIC-HF
Acute heart failure
Second Phase 3 trial initiation announced February 21, 2019.
Omecamtiv mecarbil METEORIC-HF
Acute heart failure
Phase 1 data ASCO June 2, 2019. Overall response rate 70% (7/10) in high dose, 13/42 response across all cohorts.
AMG 420
Relapsed. Refractory (R/R) Multiple Myeloma (MM)
Phase 1 data at ASH December 1, 2018 noted 12.5% ORR.
AMG 330
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
FDA approval announced December 14, 2018.
Nplate (Romiplostim)
Immune Thrombocytopenia (Pediatric)
sNDA filing announced December 19, 2018. Estimated PDUFA date October 18, 2019.
Nplate (Romiplostim)
Immune thrombocytopenia (ITP)
Phase 3 data due 2019.
Multiple Myeloma
Phase 1 trial initiation announced February 20, 2019.
AMG 594
Healthy volunteers
Phase 1 data at ASCO June 3, 2019. 50% ORR in lung cancer patients. 90% SD.
AMG 510
Solid tumors
Phase 2/3 trial discontinued due to lack of efficacy.
Alzheimer’s Disease

Latest News

  1. Article removed
  2. Wednesday’s Vital Data: Amgen, American Airlines and Apple
  3. Amgen (AMGN) Soars to 52-Week High, Time to Cash Out?
  4. Top Ranked Income Stocks to Buy for August 14th
  5. Biotech Stock Roundup: Amgen's Enbrel Patent Win, AMRN's Setback & More
  6. Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals
  7. Why This IBD Stock Of The Day Is No Longer Sweating $5 Billion In Sales
  8. Here's Why Amgen Stock is Outperforming Its Industry Of Late
  9. Mergers & Acquisitions Take Center Stage in Biotech Industry
  10. Should Value Investors Choose Amgen (AMGN) Stock Now?
  11. Is Amgen (AMGN) Outperforming Other Medical Stocks This Year?
  12. Will Amgen Continue to Surge Higher?
  13. Fear Not the Curve, Sizing Up Earnings and Ways to Play Amgen: Market Recon
  14. The Biggest Biotech Stock Is Approaching A Breakout — Here's Why
  15. Amgen wins U.S. patent battle on arthritis drug Enbrel
  16. REFILE-US STOCKS-Wall Street slides on geopolitical, recession fears
  17. Amgen stock gets boost from Friday ruling on Enbrel
  18. US STOCKS-Wall Street slips on political tensions, recession fears
  19. Top Analyst Reports: Amgen, Uber, Mondelez & More
  20. US STOCKS-Wall Street slips as trade war stokes fears of recession